Last reviewed · How we verify
NCT03600688: MiBAND
Edwards Cardioband European Post-Market Study, MiBAND
trial testing Edwards Cardioband System in Mitral Regurgitation in 200 participants. Status unknown.
30 December 2023
Quick facts
| Lead sponsor | Edwards Lifesciences |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 6 June 2018 |
| Primary completion | 30 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 17 locations across Italy, Switzerland, Germany |
Drugs / interventions tested
- Edwards Cardioband System
Conditions studied
- Mitral Regurgitation — all drugs for Mitral Regurgitation →
- Mitral Insufficiency — all drugs for Mitral Insufficiency →
- Mitral Repair — all drugs for Mitral Repair →
- Mitral Valve — all drugs for Mitral Valve →
Sponsor
Edwards Lifesciences — full company profile →
Who can join
18 and older, any sex, with Mitral Regurgitation or Mitral Insufficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To demonstrate reduction of MR with durable performance and im-provements in functional status
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03600688
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Edwards Cardioband System
Trials testing the same drug.
- NCT03016975 — Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE) · NA · terminated
Other recruiting trials for Mitral Regurgitation
Currently open trials in the same condition.
- NCT07450911 — A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System · Phase 1 · recruiting
- NCT07366723 — The Role of cardIac magNeTic rEsonance in surGical Decision Making in Patients With Severe pRimAry miTral rEgurgitation · NA · active not recruiting
- NCT07007143 — STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication fo · Phase 4 · recruiting
- NCT07108907 — Outcome Registry and Assessment of New Edge-to-Edge Repair · recruiting
- NCT06901466 — STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for O · Phase 4 · recruiting
Other Edwards Lifesciences trials
Trials by the same sponsor.
- NCT07317648 — ClearSight NextGen1 Study · NA · completed
- NCT06833476 — TTVR STRONG Under Coverage With Evidence Development (CED) Study · recruiting
- NCT06569602 — Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) · recruiting
- NCT06834516 — ClearSight Baby Cuff · completed
- NCT05957406 — SMART TRENDS Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03600688 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Edwards Lifesciences
- Last refreshed: 26 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03600688.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing